Research Study

Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML
Principal Investigator 
Donna E. Hogge

Overview

Body Locations and Systems 
Leukemia
Disorders and Conditions 
Acute Myeloid Leukemia
ClinicalTrials.gov# 
NCT01696084
Status 
Closed to Recruitment
Study Start/End 
Oct 1, 2012 to Feb 1, 2018
Locations 
Vancouver General Hospital
Name/Title 
Mabel J.Y. Ma, Research Assistant
Phone 
604-537-1433
Email Address 
mabel.ma@alumni.ubc.ca
Purpose of Study 

To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.